The VWF-GPib axis in ischaemic stroke: Lessons from animal models

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 597-604

  Denorme, Frederik ^a   De Meyer, Simon F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Animal models; Glycoprotein Ib; Stroke; Thrombo inflammation; Von Willebrand factor

Indexed keywords

GLYCOPROTEIN IB; VON WILLEBRAND FACTOR; THROMBIN RECEPTOR;

BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; EXTERNAL CAROTID ARTERY; HUMAN; MIDDLE CEREBRAL ARTERY; MORTALITY RATE; NERVE DEGENERATION; NONHUMAN; PERCUTANEOUS THROMBECTOMY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOCYTE ADHESION; ANIMAL; ANIMAL MODEL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MODELS, ANIMAL; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; STROKE; VON WILLEBRAND FACTOR;

EID: 84989182886     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-01-0036     Document Type: Review

References (89)

1. Mozaffarian D, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015; 131: e29–322.
2. Fransen PSS, et al. Time to Reperfusion and Treatment Effect for Acute Ischaemic Stroke: A Randomized Clinical Trial. J Am Med Assoc Neurol 2015; 1–7.
3. Schwamm LH, et al. Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischaemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. Circ Cardiovasc Qual Outcomes 2013; 6: 543–549.
4. Menon BK, et al. Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. Stroke 2015; 46: 989–995.
5. Emberson J, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.
6. Rha J-H, Saver JL. The impact of recanalisation on ischaemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967–973.
7. Friedrich B, et al. Distance to thrombus in acute middle cerebral artery occlusion: a predictor of outcome after intravenous thrombolysis for acute ischaemic stroke. Stroke 2015; 46: 692–6.
8. Riedel CH, et al. The importance of size: successful recanalisation by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011; 42: 1775–1777.
9. Jang IK, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920–928.
10. Eltzschig HK, Eckle T. Ischaemia and reperfusion–from mechanism to translation. Nat Med 2011; 17: 1391–1401.
11. Kidwell CS, Saver JL, Starkman S, et al. Late secondary ischaemic injury in patients receiving intraarterial thrombolysis. Ann Neurol 2002; 52: 698–703.
12. De Meyer SF, et al. Thrombo-inflammation in stroke brain damage. Stroke 2016; 1–28.
13. De Meyer SF, Stoll G, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599–606.
14. De Meyer SF, et al. Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets 2009; 9: 9–20.
15. Gresele P, Momi S. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. Handb Exp Pharmacol 2012; 210: 287–309.
16. Longa EZ, et al. Reversible middle cerebral artery occlusion without craniec-tomy in rats. Stroke 1989; 20: 84–91.
17. Hara H, et al. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cerebral Blood Flow Metabol 1996; 16: 605–611.
18. Hossmann K–A. Cerebral ischaemia: Models, methods and outcomes. Neur-opharmacology 2008; 55: 257–270.
19. Manning NW, et al. Acute ischaemic stroke: time, penumbra, and reperfusion. Stroke 2014; 45: 640–644.
20. Zhang H, et al. Wide genetic variation in the native pial collateral circulation is a major determinant of variation in severity of stroke. J Cerebral Blood Flow Metabol 2010; 30: 923–934.
21. Brott T, et al. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 1989; 20: 871–875.
22. Jovin TG, et al. Thrombectomy within 8 hours after symptom onset in ischaemic stroke. N Engl J Med 2015; 372: 2296–2306.
23. Saver JL, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015; 372: 2285–2295.
24. Campbell BCV, et al. Endovascular therapy for ischaemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372: 1009–1018.
25. Goyal M, et al. Randomized assessment of rapid endovascular treatment of ischaemic stroke. N Engl J Med 2015; 372: 1019–1030.
26. Berkhemer OA, et al. A randomized trial of intraarterial treatment for acute ischaemic stroke. N Engl J Med 2015; 372: 11–20.
27. Busch E, et al. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 1997; 778: 16–24.
28. Zhang Z, et al. A Mouse Model of Embolic Focal Cerebral Ischaemia. J Cerebral Blood Flow Metabol 1997; 17: 1081–1088.
29. Lapchak PA, et al. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced haemorrhage after thromboembolic stroke. Stroke 2000; 31: 3034–3040.
30. Kito G, Nishimura A, Susumu T, et al. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods 2001; 105: 45–53.
31. Watson BD, et al. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol 1985; 17: 497–504.
32. Rauova L. ‘Radical’ model of thrombosis. Blood Am Soc Hematol 2012; 119: 1798–1799.
33. Grome JJ, et al. Quantitation of photochemically induced focal cerebral ischaemia in the rat. J Cerebral Blood Flow Metabol 1988; 8: 89–95.
34. Laursen H, et al. Cerebrovascular permeability and brain edema after cortical photochemical infarcts in the rat. Acta Neuropathol 1993; 86: 378–385.
35. Orset C, et al. Mouse Model of In Situ Thromboembolic Stroke and Reperfusion. Stroke 2007; 38: 2771–2778.
36. Amki El M, Lerouet D, Coqueran B, et al. Experimental modeling of recombinant tissue plasminogen activator effects after ischaemic stroke. Exp Neurol 2012; 238: 138–144.
37. Garcia-Yebenes I, et al. A Mouse Model of Haemorrhagic Transformation by Delayed Tissue Plasminogen Activator Administration After In Situ Thromboembolic Stroke. Stroke 2010; 42: 196–203.
38. Hill MD, Coutts SB. Alteplase in acute ischaemic stroke: the need for speed. Lancet 2014; 1–2.
39. Ansar S, et al. Characterisation of a New Model of Thromboembolic Stroke in C57 black/6J mice. Transl Stroke Res 2013; 5: 526–533.
40. Karatas H, et al. Thrombotic distal middle cerebral artery occlusion produced by topical FeCl3 application: a novel model suitable for intravital microscopy and thrombolysis studies. J Cerebral Blood Flow Metabol 2011; 31: 1452–1460.
41. Ciciliano JC, et al. Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood 2015; 126: 817–824.
42. Le Behot A, et al. GpIb-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood 2014; 123: 3354–3363.
43. Denorme F, et al. ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischaemic stroke in mice. Blood 2016; Epub ahead of print.
44. De Meyer SF, et al. von Willebrand factor to the rescue. Blood 2009; 113: 5049–5057.
45. Ruggeri ZM, et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903–1910.
46. Levy GG, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488–494.
47. Petri B, et al. von Willebrand factor promotes leukocyte extravasation. Blood 2010; 116: 4712–4719.
48. Bernardo A, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005; 3: 562–570.
49. Pendu R, et al. P-selectin glycoprotein ligand 1 and β2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 2006; 108: 3746–3752.
50. Gandhi C, et al. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischaemia/reperfusion injury in mice. Blood 2012; 120: 5224–5230.
51. Kleinschnitz C, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323–2330.
52. De Meyer SF, et al. Platelet glycoprotein Ibα is an important mediator of ischaemic stroke in mice. Exp Transl Stroke Med 2011; 3: 9.
53. Stegner D, et al. Pharmacological Inhibition of Phospholipase D Protects Mice From Occlusive Thrombus Formation and Ischaemic Stroke--Brief Report. Arterioscl Thromb Vasc Biol 2013; 33: 2212–2217.
54. Thielmann I, et al. Redundant functions of phospholipases D1 and D2 in platelet α-granule release. J Thromb Haemost 2012; 10: 2361–2372.
55. Kleinschnitz C, et al. Deficiency of von Willebrand factor protects mice from ischaemic stroke. Blood 2009; 113: 3600–3603.
56. Zhao BQ, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischaemic brain injury in experimental stroke. Blood 2009; 114: 3329–3334.
57. De Meyer SF, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischaemic stroke in mice--brief report. Arterioscl Thromb Vasc Biol 2010; 30: 1949–1951.
58. Verhenne S, et al. Platelet-derived VWF is not essential for normal thrombosis and haemostasis but fosters ischaemic stroke injury in mice. Blood 2015; 126: 1715–1722.
59. Fujioka M, et al. ADAMTS13 gene deletion aggravates ischaemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischaemic hypoperfusion. Blood 2010; 115: 1650–1653.
60. Khan MM, et al. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischaemia in mice. J Thromb Haemost 2012; 10: 1665–1671.
61. Wang L, et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced haemorrhage after stroke in mice. Ann Neurol 2012; 73: 189–198.
62. Li T-T, et al. A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. Br J Pharmacol 2015; 172: 3904–3916.
63. Nieswandt B, et al. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011; 589: 4115–4123.
64. Prabhakaran S, et al. Acute Stroke Intervention: A Systematic Review. J Am Med Assoc 2015; 313: 1451–1462.
65. Nieswandt B, Stoll G. (Dis) solving the stroke problem by vWF inhibition? Blood 2013; 128: 4972–4974.
66. Lapchak PA, et al. Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits. J Neurol Neurophysiol 2013; 4: doi: 10.4172/2155–9562.1000146.
67. Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood 2013; 121: 5088–5097.
68. Fisher M, et al. Update of the stroke therapy academic industry roundtable pre-clinical recommendations. Stroke 2009; 40: 2244–2250.
69. Kraft P, et al. Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke. Stroke 2015; 46: 3502–3506.
70. Kleinschnitz C, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323–2330.
71. Adams HP, et al. Emergency administration of abciximab for treatment of patients with acute ischaemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87–99.
72. Kellert L, et al. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral haemorrhage and poor outcome. Stroke 2013; 44: 1453–1455.
73. Siebler M, et al. Safety of Tirofiban in Acute Ischaemic Stroke: The SaTIS Trial. Stroke 2011; 42: 2388–2392.
74. Wieberdink RG, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010; 41: 2151–2156.
75. Sonneveld MAH, et al. Low ADAMTS13 activity is associated with an increased risk of ischaemic stroke. Blood 2015; 126: 2739–2746.
76. Sonneveld MAH, et al. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 2014; 28: 167–178.
77. Sanders YV, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11: 845–854.
78. Seaman CD, et al. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost 2015; 13: 1999–2003.
79. Carter AM, et al. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscl Thromb Vasc Biol 1998; 18: 1124–1131.
80. Bustamante A, et al. Abstract 189: ADAMTS13 Activity Predicts Response to Thrombolysis in the Acute Stroke Setting. Stroke 2015; 46: A189–189.
81. Kageyama S, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscl Thromb Vasc Biol 2002; 22: 187–192.
82. Machin SJ, et al. A humanized monoclonal antibody against VWF A1 domain inhibits VWF: RiCof activity and platelet adhesion in human volunteers. J Thromb Haemost; 2003; 1: Abstract OC328.
83. Gilbert JC, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678–2686.
84. Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior pre-clinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011; 118: 757–765.
85. Jilma-Stohlawetz P, et al. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012; 108: 284–290.
86. Jilma-Stohlawetz P, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545–552.
87. Knöbl P, et al. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 2181–2185.
88. Holz J-B. The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfusion Apheresis Sci 2012; 46: 343–346.
89. Peyvandi F, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2016; 374: 511–522.